Dictionary

allow_url_fopen is ENABLED Dictionary Search

gossamer

Synonyms

Adjective

1. ethereal

2. delicate, diaphanous

Noun

1. filmy, gauzy, see-through, sheer, transparent, vaporous, cobwebby, thin, gauze

2. netting, veiling, cobweb

3. fibril, filament, strand

Usage
Gossamer Gear's New Tents Achieve UL Innovation With an Old-School Feature - Field Mag
Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes - Yahoo Finance
Gossamer Gear The Free 1P: a 845-gram Freestanding Tent - BIKEPACKING.com
Storm-Ready Solo Backpack Tents - Trend Hunter
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc - The National Law Review
Gossamer Nearly Halves Workforce in Savings Push After Late-Stage Hypertension Fail - BioSpace
Latham Represents Gossamer Bio Inc in Exchange Offer and Consent Solicitation Transaction - Latham & Watkins LLP
Gossamer Gear Skala 38 Review - The Trek
What to expect from Gossamer Bio’s late-stage lung disease study - STAT
Gossamer Bio reports topline Phase III PROSERA outcomes for PAH - Clinical Trials Arena
Free tent reignites intense 2-lb ultralight backpacking competition - New Atlas
Gossamer Gear Just Unveiled the Lightest Framed Pack Ever - Backpacker Magazine
Context Capital (GOSS) discloses 48.8M-share, 9.9% stake in Gossamer Bio - Stock Titan
Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk - Yahoo Finance
On the Trail With Gossamer Gear's Mirage Ultralight 40L Pack - Field Mag
Gossamer Gear Grit 28 Review: Is a 14oz Fastpack for Under $200 Too Good To Be True? - The Trek
How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations - Yahoo Finance
How The Gossamer Bio (GOSS) Story Is Shifting After The PROSERA Miss And Cash Concerns - Yahoo Finance
Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS) - Yahoo Finance
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- Hagens Berman - PR Newswire
Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback - Yahoo Finance
Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail - Fierce Biotech
A Look At Gossamer Bio (GOSS) Valuation After Barclays Strong Buy Upgrade And Rising Institutional Ownership - Yahoo Finance
‘Like a Gossamer Sheet’ - The New York Review of Books
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty - BioSpace
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Gossamer Bio (NASDAQ: GOSS) swaps most 2027 converts into 2030 debt and equity - Stock Titan
Gossamer Bio Insiders Are Down US$45k But Regain Some Losses - simplywall.st
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - PR Newswire
How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals - Yahoo Finance
Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback - Yahoo Finance
Gossamer Bio shares plummet as lung disease drug fails late-stage trial - Reuters
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support - Business Wire
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallSt - PR Newswire
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update - Business Wire
Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval - STAT
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
This Lightweight Umbrella Protected Us From Sun, Rain, and Even Hail - The New York Times
Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to Neutral - Yahoo Finance
How Gossamer Gear Made a UL Backpacking Comeback - Field Mag
Gossamer Bio options imply 46.1% move in share price post-earnings - Yahoo Finance
Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue - Yahoo Finance
Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - BioSpace
Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation - Yahoo Finance
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update - Business Wire
Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline - Yahoo Finance
With 63% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big guns - Yahoo Finance
The Best Ultralight Backpack of 2026 - GearLab
Gossamer Bio Inc. (GOSS) Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Shares - Return On Assets - lwvtexas.org
Analysts Revise Forecasts for Gossamer Bio (GOSS) Amid Uncertain Regulatory Environment - Yahoo Finance
Gossamer Sees Path To Market For Seralutinib After It Fails In Phase III PAH Trial - insights.citeline.com
GOSS - Gossamer Bio Inc Stock Price and Quote - Finviz
Why Analysts Say Gossamer Bio’s Story Is Changing Ahead of Critical Clinical Milestones - Yahoo Finance
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension - Yahoo Finance
David E. Shaw Discloses Investment at Gossamer Bio with 9.5% Stake - TradingView
Oppenheimer Confident in Positive PROSERA Trial Readout in February 2026 for Gossamer Bio (GOSS) - Yahoo Finance
Packing Doesn't Stress Me Out Anymore Thanks to the Organizational Genius of This Travel Backpack - Outside Magazine
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky - Business Wire
GOSS Investor Alert - Gossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - Morningstar
Robbins LLP Encourages GOSS Stockholders Who Lost Money Investing in Gossamer Bio, Inc. to Contact the Firm for Information About Leading the Class Action - Morningstar
Gossamer Bio’s Phase 3 PROSERA PAH Trial Misses Primary Endpoint Despite Numerical 6MWD Gain - Yahoo Finance
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - GlobeNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - GlobeNewswire
Gossamer Bio (GOSS) Quarterly Loss Deepens To US$47 Million Testing Bullish Profitability Narrative - simplywall.st
A Big Test For Seralutinib - Will Gossamer's PAH Data Win Investors' Hearts This Month? - RTTNews
Gossamer Gear Mariposa 60 Backpack Review - Switchback Travel
Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data - Yahoo Finance
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
Earnings call transcript: Gossamer Bio Q1 2026 sees revenue beat, EPS miss - Investing.com
Gossamer Bio stock tumbles 80% on trial miss - Investing.com
A Look At Gossamer Bio (GOSS) Valuation As PROSERA Phase 3 Seralutinib Results Shape Next Steps - simplywall.st
Bragar Eagel & Squire, P.C. Reminds Gossamer Investors that - GlobeNewswire
Gossamer Bio, Inc. (GOSS) Stock Analysis: Unpacking The 909.78% Potential Upside - DirectorsTalk Interviews
Rosen Law Firm Urges Gossamer Bio, Inc. (NASDAQ: GOSS) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action - GlobeNewswire
Latham & Watkins Advises Gossamer Bio in Option Agreement to Acquire Respira Therapeutics - Latham & Watkins LLP
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Placebo Response Risks: Levi & Korsinsky - Morningstar
Reply to Fleming: Not a gossamer web - PNAS
Gossamer Bio Q1 Earnings Call Highlights - TradingView
Frankfort High School drama club to present ‘Gossamer’ - State-Journal
Gossamer Bio: High Risk Binary Approaches (NASDAQ:GOSS) - Seeking Alpha
GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & - GlobeNewswire
INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with - GlobeNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - GlobeNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS - TradingView
Gossamer Bio extends early tender date for exchange offer; $181.05M tendered, New Notes up to $72M - TradingView
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, - GlobeNewswire
Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who - GlobeNewswire
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action - GlobeNewswire
Foreign Language Equivalents
Foreign Language Equivalents of 'gossamer'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
gosdamer,   gosssamer,   hossamer,   gossaner,   gosssamer,   gpssamer,   gossamor,   gossamr,   gossmaer,   gossamerr,   godsamer,   gossamwr,   gossameer,   gossammer,   gissamer,   gossa,er,   gossaer,   gosamer,   gossamrr,   gossamet,   gossamre,   goasamer,   gossmer,   gossamee,   gossaemr,   ossamer,   gosasmer,   ggossamer,   gosssmer,   gssamer,   goossamer,   fossamer,   gsosamer,   gossame,   gossaamer,   ogssamer,   gosaamer,   gosamer
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z